Hussman Strategic Advisors, Inc. Exelixis, Inc. Transaction History

Hussman Strategic Advisors, Inc.

$417 Million
Q1 2024

A detailed history of Hussman Strategic Advisors, Inc. transactions in Exelixis, Inc. stock. As of the latest transaction made, Hussman Strategic Advisors, Inc. holds 147,000 shares of EXEL stock, worth $3.3 Million. This represents 0.84% of its overall portfolio holdings.

Number of Shares

147,000

Previous 147,000 -0.0%

Holding current value

$3.3 Million

Previous $3.53 Million 1.08%

% of portfolio

0.84%

Previous 0.81%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 01, 2024	BUY	$19.25 - $24.13 $327,250 - $410,210	17,000 Added 13.08%	147,000 $3.53 Million
Q2 2023 Aug 03, 2023	SELL	$18.17 - $20.48 $454,250 - $512,000	-25,000 Reduced 16.13%	130,000 $2.48 Million
Q3 2022 Nov 02, 2022	BUY	$15.68 - $22.27 $2.02 Million - $2.87 Million	129,000 Added 496.15%	155,000 $2.43 Million
Q1 2022 May 04, 2022	SELL	$17.03 - $22.67 $85,150 - $113,350	-5,000 Reduced 16.13%	26,000 $589,000
Q3 2021 Nov 01, 2021	SELL	$16.3 - $21.14 $505,300 - $655,340	-31,000 Reduced 50.0%	31,000 $655,000

Q2 2021 Aug 03, 2021	SELL	$17.95 - $25.56 $547,475 - $779,580	-30,500 Reduced 32.97%	62,000 $1.13 Million
Q1 2021 May 03, 2021	SELL	$20.53 - $25.22 $205,300 - $252,200	-10,000 Reduced 9.76%	92,500 $2.09 Million
Q4 2020 Feb 01, 2021	BUY	$18.39 - $24.8 $478,140 - $644,800	26,000 Added 33.99%	102,500 $2.06 Million
Q2 2020 Jul 31, 2020	SELL	$16.46 - $27.42 $831,230 - $1.38 Million	-50,500 Reduced 39.76%	76,500 $1.82 Million
Q1 2020 May 01, 2020	BUY	$14.46 - $21.8 $361,500 - $545,000	25,000 Added 24.51%	127,000 $2.19 Million
Q3 2019 Oct 31, 2019	BUY	$17.68 - $22.65 $1.8 Million - $2.31 Million	102,000 New	102,000 $1.8 Million

Others Institutions Holding EXEL

# of Institutions

459

Shares Held

246M

Call Options Held

1.7M

Put Options Held

1.02M

View Full List

About EXELIXIS, INC.

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $7.23B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

More about EXEL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Hussman Strategic Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Hussman Strategic Advisors, Inc. with notifications on news.

Account

Hussman Strategic Advisors, Inc. Exelixis, Inc. Transaction History